SSA
TNGX icon

Schonfeld Strategic Advisors’s Tango Therapeutics TNGX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120,689
Closed -$2.52M – 3005
2026
Q1 		$2.52M Buy
+120,689
New +$1.68M 0.02% 728
2024
Q1 		– Sell
-56,400
Closed -$558K – 2411
2023
Q4 		$558K Buy
56,400
+15,106
+37% +$131K ﹤0.01% 1246
2023
Q3 		$465K Buy
+41,294
New +$252K ﹤0.01% 1224
2022
Q4 		– Sell
-16,000
Closed -$58K – 3008
2022
Q3 		$58K Buy
+16,000
New +$68.3K ﹤0.01% 2623

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Schonfeld Strategic Advisors's TNGX Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 120,689 shares — an estimated $2.52M sold.

Schonfeld Strategic Advisors first reported a position in TNGX in Q3 2022 and held it in 4 quarters. The position peaked at $2.52M in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 120,689 Tango Therapeutics shares in Q2 2026, an estimated $2.52M.
  • Schonfeld Strategic Advisors first reported a position in Tango Therapeutics in Q3 2022 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Tango Therapeutics position peaked at $2.52M in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.